This 2023 statement updates clinical guidance for homozygous familial
hypercholesterolaemia (HoFH), explains the genetic complexity, and provides pragmatic …

This contemporary, international, evidence-informed guidance aims to achieve the greatest
good for the greatest number of people with familial hypercholesterolaemia (FH) across …

Background: Mutations in low-density lipoprotein (LDL) receptor (LDLR) are one of the main
causes of familial hypercholesterolemia, which induces atherosclerosis and has a high …

Background and aims Management of familial hypercholesterolaemia (FH) may vary across
different settings due to factors related to population characteristics, practice, resources …

Abstract Purpose of Review Familial hypercholesterolemia (FH) is the most common genetic
metabolic disorder characterized by markedly elevated LDL-C levels from birth leading to …

Optimal care for familial hypercholesterolaemia (FH) requires patient-centred management,
multidisciplinary teamwork, involvement of primary care practitioners, patient networks …

Familial hypercholesterolemia (FH) is one of the most common monogenic diseases,
leading to an increased risk of premature atherosclerosis and its cardiovascular …

Aim Our aim was to assess the efficacy and safety of mipomersen through a systematic
review of the literature and a meta-analysis of the available clinical studies. Methods A …

Familial hypercholesterolaemia (FH) is a dominant and highly penetrant monogenic
disorder present from birth that markedly elevates plasma low-density lipoprotein (LDL) …

The discovery of bioactive molecules is an expensive and time-consuming process and new
strategies are continuously searched for in order to optimize this process. Virtual Screening …